Trial Details
Not RecruitingBasic Information
| Clinical ID | c2642 |
|---|---|
| Identifier | EUCTR2019-000717-37-ES |
| Trial Title | LOSS OF RESPONSE OF THE ADALIMUMAB BIOSIMILAR COMPARED WITH THE LOSS OF RESPONSE OF THE ADALIMUMAB ORIGINAL: CONTROLLED, RANDOMIZED, NON-INFERIORITY OPEN STUDY._ADA-SWITCH Study - ADA-SWITCH Study |
| Trial URL | Visit Original Page |
Study Information
| Study Results | No results available |
|---|---|
| Conditions | Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] |
| Interventions | Trade Name: Amgevita Product Name: AMGEVITA (Adalimumab biosimilar ) Pharmaceutical Form: Solution for injection Trade Name: HUMIRA Product Name: Humira (adalimumab original) Pharmaceutical Form: Solution for injection |
Participant Information
| Sponsor | Fundacin Publica Andaluza para la Gestin de Salud en Sevilla (FISEVI) |
|---|---|
| City | - |
| Country/Region | Spain |
Enrollment Criteria
| Sex Requirement | NOT SPECIFIED |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional clinical trial of medicinal product |
|---|---|
| Phase | PHASE4 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | - |
| Completion Date | - |